|
|
Рассылка закрыта
Подпишитесь на другие актуальные форекс рассылки:
02 июня 2017 в 18:30
Биотех в субботу June 3, 2017 BiotechnologyУважаемые наши подписчики!
ARQL Phase 2
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2
Phase 2 enrollment completed. Poster discussion at ASCO June 3, 2017. Phase 3 trial planned for 3Q 2017. Мат.ожидание район 3.20 __ CYTR Phase 3
Aldoxorubicin with doxorubicin Soft tissue sarcomas refractory cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017. Oral presentation ASCO June 3, 2017. Abstract 11000.
-- DVAX Phase 1b/2
SD-101 + Pembrolizumab Melanoma - cancer Phase 1/2
Phase 1b/2 poster at ASCO June 3, 2017. Abstract 9550.
--
IMGN Phase 1b
Mirvetuximab soravtansine - FORWARD II Ovarian cancer and relapsed endometrial cancer Phase 1/2
Phase 1b safety data at ASCO June 3, 2017. Abstract 5553.
-- LPTX Phase 1
DKN-01 Biliary tract cancer (BTC) Phase 1
Phase 1 data due at ASCO June 3, 2017. Abstract 4075.
-- MTNB Phase 2a
MAT2203 Refractory mucocutaneous candidiasis
Phase 2a open label data due June 3, 2017 at ASM Microbe.
-
PIRS Phase 1b
PRS-080 Anemia of chronic disease Phase 1b
Phase 1b data due at ERA-EDTA June 3-6, 2017. Exact date TBC.
---
SNDX Phase 2 trial
Entinostat plus Keytruda - ENCORE 601 Recurrent non-small cell lung cancer (NSCLC) Phase 1/2
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Poster presentation at ASCO June 3, 2017.
-- TGTX Phase 3 trial
TG-1101 and IMBRUVICA (GENUINE trial) Chronic Lymphocytic Leukemia (CLL) cancer Phase 3
Phase 3 trial met primary endpoint - March 6, 2017, meeting with FDA in 2H 2017. Oral presentation at ASCO June 3, 2017. Abstract 7504.
C уважением, S&V Tradeprofi Ltd. Добро пожаловать в наш новый ЧАТ - http://chat.tradeprofi.com/ IOS,WIN,WEB,LINUX ... Секреты успеха http://goo.gl/56Jmx Наш проект http://tradeprofi.eu
Отзывы, комментарии об этом выпуске
|
|
Вход в FxMail.ru